InvestorsHub Logo
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: None

Friday, 01/08/2021 9:02:18 AM

Friday, January 08, 2021 9:02:18 AM

Post# of 3017
ENTA announces two new programs: 1) an oral HBV RNA destablizer; and 2) an RSV-L inhibitor. These are possible combination agents for ENTA’s existing compounds, EDP-514 and EDP-938, respectively.

https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-to-Provide-Updates-on-its-Research-and-Development-Programs-and-Outlook-for-2021-at-the-39th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News